Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Apply to the University of Wyoming apply now

Global Resource Navigation

Visit Campus
Download UW Viewbook
Give to UW
Menu

Contact Us

Wyoming Drug Utilization Review (WY-DUR)

Dept. 3375

1000 E. University Ave.

Laramie, WY 82070

Phone: 307-766-6750

Fax: 307-766-2953

Email: lgm@uwyo.edu

Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org. 

The Draft 2018 PDL, effective January 1, 2018, is available for review.

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 2, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the November 9, 2017 P & T Committee meeting.

  • Trokendi XR will require prior authorization for migraine.  Patients will be directed to other forms of topiramate.

  • The Angiotensin Receptor blockers (ARBs) will no longer require a step through an ACE Inhibitor. 

  • PCSK9s criteria will be updated to include secondary prevention of ASCVD in patients who have not met goal with a maximum dose of a high-potency statin.  Familial hypercholesterolemia will continue to be approved. 

  • Austedo will be approved for tardive dyskinesia based on its recent approval. 

  • Tremfya has superiority data over Humira.  As such, it was recommended as a preferred agent for plaque psoriasis. 

  • Imbruvica will be limited to indication for graft versus host disease.  This will not affect its use in cancer therapy. 

  • Haegarda, Mavyret, Bevyxxa and Benlysta will all be limited to indication.  Mavyret will also have the Hepatitis C class criteria applied. 

  • Effective January 1, 2018, Xiidra will be non-preferred to Restasis.  A 12 week trial and failure of Restasis will be required prior to approval of Xiidra. 

  • Hemophilia agents were reviewed.  There is no comparative evidence in this class.  The Committee requested that all patients be grandfathered should a restrictive PDL be created.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to February 1, 2018.

P & T Committee Meeting Dates

Agenda November 9, 2017

Minutes November 9, 2017

2018 Meetings

Thursday, February 8; Thursday, May 3; Thursday, August 9; Thursday, November 8

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.


Share This Page:


Contact Us

Wyoming Drug Utilization Review (WY-DUR)

Dept. 3375

1000 E. University Ave.

Laramie, WY 82070

Phone: 307-766-6750

Fax: 307-766-2953

Email: lgm@uwyo.edu

1000 E. University Ave. Laramie, WY 82071
UW Operators (307) 766-1121 | Contact Us | Download Adobe Reader

Twitter Icon Youtube Icon Instagram Icon Facebook Icon

Accreditation | Emergency Preparedness | Employment at UW | Gainful Employment | Privacy Policy | Accessibility Accessibility information icon